# Combination Chemotherapy After Surgery in Treating Patients With High-Risk Stage II or Stage III Colorectal Cancer

> **NCT00749450** · PHASE3 · COMPLETED · sponsor: **Cancer Research UK, Glasgow** · enrollment: 6088 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** capecitabine
- **DRUG:** fluorouracil
- **DRUG:** oxaliplatin

## Key facts

- **NCT ID:** NCT00749450
- **Lead sponsor:** Cancer Research UK, Glasgow
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2017-11
- **Final completion:** —
- **Target enrollment:** 6088 (ACTUAL)
- **Last updated:** 2018-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00749450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00749450, "Combination Chemotherapy After Surgery in Treating Patients With High-Risk Stage II or Stage III Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00749450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*